Loading
French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials.
Laurence Albiges was a lead investigator of CheckMate 214 (nivolumab plus ipilimumab) and of the LITESPARK trials that established belzutifan, the first HIF-2 alpha inhibitor, for previously treated clear-cell renal cell carcinoma. She led the CheckMate 214 long-term follow-up analyses and chairs the ESMO renal cancer guideline group. She heads medical oncology at Gustave Roussy.
Shares CheckMate 214, Ipilimumab, Renal cell carcinoma, Nivolumab and the tag rcc.
Shares CheckMate 214, Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares LITESPARK-005, HIF-2α, Belzutifan, Renal cell carcinoma.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors and the tag rcc.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors.
Shares Renal cell carcinoma, PD-1, Immune checkpoint inhibitors and the tag rcc.
Shares CheckMate 214, Ipilimumab, Nivolumab.
Shares Gustave Roussy, Ipilimumab, Nivolumab, PD-1.